AstraZeneca and Saint Luke’s Mid America Heart Institute have initiated a randomized, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients hospitalized with COVID-19 who are at risk of developing serious complications, such as organ failure. Read more...
Theravance Biopharma announced the first healthy volunteer has been dosed in a Phase 1 study of TD-0903. TD-0903 is a lung-selective, nebulized Janus kinase inhibitor (JAKi) in development for the potential treatment of hospitalized patients with Acute Lung Injury (ALI) caused by COVID-19. Read more...
The U.S. Food and Drug Administration (FDA) has authorized the first diagnostic test with a home collection option for COVID-19. Read more...
Immunic reported that its lead asset, IMU-838, a selective oral DHODH inhibitor, has successfully demonstrated preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Read more...